Use of MRNA COVID-19 Vaccine After Reports of Myocarditis Among Vaccine Recipients : Update From the Advisory Committee on Immunization Practices — United States, June 2021

Details

• Personal Author:
  Yard, Ellen ; Radhakrishnan, Lakshmi ; Ballesteros, Michael F. ; Sheppard, Michael ; Gates, Abigail ; Stein, Zachary ; Hartnett, Kathleen ; Kite-Powell, Aaron ; Rodgers, Loren ; Adjemian, Jennifer ; Ehlman, Daniel C. ; Holland, Kristin ; Idaikkadar, Nimi ; Ivey-Stephenson, Asha ; Martinez, Pedro ; Law, Royal ; Stone, Deborah M.
• Corporate Authors:
  National Center for Injury Prevention and Control (U.S.). ; Center for Surveillance, Epidemiology, and Laboratory Services (U.S.)
• Description:
  What is already known about this topic? An elevated risk for myocarditis among mRNA COVID-19 vaccinees has been observed, particularly in males aged 12–29 years.
  
  What is added by this report? On June 23, 2021, the Advisory Committee on Immunization Practices concluded that the benefits of COVID-19 vaccination to individual persons and at the population level clearly outweighed the risks of myocarditis after vaccination.
  
  What are the implications for public health practice? Continued use of mRNA COVID-19 vaccines in all recommended age groups will prevent morbidity and mortality from COVID-19 that far exceed the number of cases of myocarditis expected. Information regarding the risk for myocarditis with mRNA COVID-19 vaccines should be disseminated to providers to share with vaccine recipients.
  
  In December 2020, the Food and Drug Administration (FDA) issued Emergency Use Authorizations (EUAs) for the Pfizer-BioNTech COVID-19 (BNT162b2) vaccine and the Moderna COVID-19 (mRNA-1273) vaccine,† and the Advisory Committee on Immunization Practices (ACIP) issued interim recommendations for their use in persons aged ≥16 years and ≥18 years, respectively.§ In May 2021, FDA expanded the EUA for the Pfizer-BioNTech COVID-19 vaccine to include adolescents aged 12–15 years; ACIP recommends that all persons aged ≥12 years receive a COVID-19 vaccine. Both Pfizer-BioNTech and Moderna vaccines are mRNA vaccines encoding the stabilized prefusion spike glycoprotein of SARS-CoV-2, the virus that causes COVID-19. Both mRNA vaccines were authorized and recommended as a 2-dose schedule, with second doses administered 21 days (Pfizer-BioNTech) or 28 days (Moderna) after the first dose. After reports of myocarditis and pericarditis in mRNA vaccine recipients,¶ which predominantly occurred in young males after the second dose, an ACIP meeting was rapidly convened to review reported cases of myocarditis and pericarditis and discuss the benefits and risks of mRNA COVID-19 vaccination in the United States. Myocarditis is an inflammation of the heart muscle; if it is accompanied by pericarditis, an inflammation of the thin tissue surrounding the heart (the pericardium), it is referred to as myopericarditis. Hereafter, myocarditis is used to refer to myocarditis, pericarditis, or myopericarditis. On June 23, 2021, after reviewing available evidence including that for risks of myocarditis, ACIP determined that the benefits of using mRNA COVID-19 vaccines under the FDA’s EUA clearly outweigh the risks in all populations, including adolescents and young adults. The EUA has been modified to include information on myocarditis after receipt of mRNA COVID-19 vaccines. The EUA fact sheets should be provided before vaccination; in addition, CDC has developed patient and provider education materials about the possibility of myocarditis and symptoms of concern, to ensure prompt recognition and management of myocarditis.
  
  Suggested citation for this article: Gargano JW, Wallace M, Hadler SC, et al. Use of mRNA COVID-19 Vaccine After Reports of Myocarditis Among Vaccine Recipients: Update from the Advisory Committee on Immunization Practices — United States, June 2021. MMWR Morb Mortal Wkly Rep. ePub: 6 July 2021
  
  mm7027e2.htm?s_cid=mm7027e2_w
  
  mm7027e2-H.pdf
  
  
• Subjects:
  Betacoronavirus/genetics Coronavirus Coronavirus Infections COVID-19/genetics Genomics Pneumonia, Viral SARS-CoV-2
• Source:
  MMWR: Morbidity and Mortality Weekly Report 2021; v. 70 Early Release
• Series:
  Weekly Report: Morbidity and Mortality Weekly Report (MMWR)
• ISSN:
  0149-2195 (print) ; 1545-861X (digital)
• Document Type:
  Journal Article
• Name as Subject:
  National Syndromic Surveillance Program
• Place as Subject:
  United States
• Location:
  North America
• Pages in Document:
  6 pdf pages
• Volume:
  70
• Collection(s):
  Advisory Committee on Immunization Practices (ACIP) Morbidity and Mortality Weekly Report (MMWR)
• Main Document Checksum:
  urn:sha-512:144d49d81fdb9c667c939d863e21c07f3130e8f9265ab988f2a0d10ae388f14fc1afa7e39868e9de2adbe46c32627f077a4ad7f28a2c3fc6c3b4644e70c1aa77
• Download URL:
  https://stacks.cdc.gov/view/cdc/107702/cdc_107702_DS1.pdf
• File Type:
  [PDF - 222.24 KB ]